Lattice_grid_med
Powered by LatticeGrid

Search Enter term and hit return. Use '*' for as a wildcard.

Publication Listing for the MeSH term RADICAL PROSTATECTOMY. Found 13 abstracts

Kim SP, Gross CP, Nguyen PY, Smaldone MC, Thompson RH, Shah ND, Kutikov A, Han LC, Karnes RJ, Ziegenfuss JY, Tilburt JC. Specialty bias in treatment recommendations and quality of life among radiation oncologists and urologists for localized prostate cancer. Prostate Cancer and Prostatic Diseases. 2014 Jun;17(2):163-9.   PMCID: No NIH funding
Michalski JM, Roach M, Merrick G, Anscher MS, Beyer DC, Lawton CA, Lee WR, Pollack A, Rosenthal SA, Vijayakumar S, Carroll PR. ACR Appropriateness Criteria (R) on External Beam Radiation Therapy Treatment Planning for Clinically Localed Prostate Cancer Expert Panel on Radiation Oncology-Prostate. International Journal of Radiation Oncology Biology Physics. 2009 Jul;74(3):667-72.
Putt M, Long JA, Montagnet C, Silber JH, Chang VW, Liao KJ, Schwartz JS, Pollack CE, Wong YN, Armstrong K. Racial Differences in the Impact of Comorbidities on Survival Among Elderly Men With Prostate Cancer. Medical Care Research and Review. 2009 Aug;66(4):409-35.   PMCID: PMC2780425
Wong YN, Freedland S, Egleston B, Hudes G, Schwartz JS, Armstrong K. Role of Androgen Deprivation Therapy for Node-Positive Prostate Cancer. Journal of Clinical Oncology. 2009 Jan;27(1):100-5.   PMCID: PMC 2645095
Zubek VB, Konski A. Cost Effectiveness of Risk-Prediction Tools in Selecting Patients for Immediate Post-Prostatectomy Treatment. Molecular Diagnosis & Therapy. 2009 Jan;13(1):31-47.
Trabulsi EJ, Valicenti RK, Hanlon AL, Pisansky TM, Sandler HM, Kuban DA, Catton CN, Michalski JM, Zelefsky MJ, Kupelian PA, Lin DW, Anscher MS, Slawin KM, Roehrborn CG, Forman JD, Liauw SL, Kestin LL, DeWeese TL, Scardino PT, Stephenson AJ, Pollack A. A Multi-Institutional Matched-Control Analysis of Adjuvant and Salvage Postoperative Radiation Therapy for pT3-4N0 Prostate Cancer. Urology. 2008 Dec;72(6):1298-302.
Williams SG, Buyyounouski MK, Pickles T, Kestin L, Martinez A, Hanlon AL, Duchesne GM. Percentage of biopsy cores positive for malignancy and biochemical failure following prostate cancer radiotherapy in 3,264 men: Statistical significance without predictive performance. International Journal of Radiation Oncology Biology Physics. 2008 Mar;70(4):1169-75.
D'Ambrosio DJ, Hanlon AL, Al-Saleem T, Feigenberg SJ, Horwitz EM, Uzzo RG, Pollack A, Buyyounouski MK. The proportion of prostate biopsy tissue with Gleason pattern 4 or 5 predicts for biochemical and clinical outcome after radiotherapy for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2007 Mar;67(4):1082-7.
Valicenti RK, DeSilvio M, Hanks GE, Porter A, Brereton H, Rosenthal SA, Shipley WU, Sandler HM, Haile RW, Thomas DC, McGuire V, Felberg A, John EM, Milne RL, Hopper JL, Jenkins MA, Levine AJ, Daly MM, Buys SS, Senie RT, Andrulis IL, Knight JA, Godwin AK, Southey M, McCredie MR, Giles GG, Andrews L, Tucker K, Miron A, Apicella C, Tesoriero A, Bane A, Pike MC, Whittemore AS. Posttreatment prostatic-specific antigen doubling time as a surrogate endpoint for prostate cancer-specific survival: An analysis of radiation therapy oncology group protocol 92-02 BRCA1 and BRCA2 mutation carriers, oral contraceptive use, and breast cancer before age 50. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS LA English DT Article DE prostate cancer; prostate-specific antigen doubling time; mortality; surrogate endpoint. 2006 Oct;15(10):1863-70.
Bruner DW, Hanlon A, Mazzoni S, Raysor S, Konski A, Hanks G, Pollack A. Predictors of preferences and utilities in men treated with 3D-CRT for prostate cancer. International Journal of Radiation Oncology Biology Physics. 2004 Jan;58(1):34-42.
Chism DB, Hanlon AL, Horwitz EM, Feigenberg SJ, Pollack A. A comparison of the single and double factor high-risk models for risk assignment of prostate cancer treated with 3D conformal radiotherapy. International Journal of Radiation Oncology Biology Physics. 2004 Jun;59(2):380-5.
Jacob R, Hanlon AL, Horwitz EM, Movsas B, Uzzo RG, Pollack A. The relationship of increasing radiotherapy dose to reduced distant metastases and mortality in men with prostate cancer. Cancer. 2004 Feb;100(3):538-43.
Kuban DA, Thames HD, Levy LB, Horwitz EM, Kupelian PA, Martinez AA, Michalski JM, Pisansky TM, Sandler HM, Shipley WU, Zelefsky MJ, Zietman AL. Long-term multi-institutional analysis of stage T1-T2 prostate cancer treated with radiotherapy in the PSA era. Int J Radiat Oncol Biol Phys. 2003 Nov 15;57(4):915-28.
The above publications are sorted by year, faculty last name, and first author. Click on any highlighted author listed to find all publications attributed to that individual. Click on the publication title to see the abstract. First authors who are faculty are highlighted like this. Last authors who are faculty are highlighted like this. Other authors who are faculty are highlighted like this.

MeSH cloud from publications including the MeSH term RADICAL PROSTATECTOMY

RADICAL PROSTATECTOMY RECURRENCE KeyWords Plus: RADIATION-THERAPY prostate cancer IRRADIATION CARCINOMA RISK RADIOTHERAPY radiotherapy OUTCOMES FAILURE ADENOCARCINOMA EXTERNAL-BEAM RADIATION MEN ANTIGEN BIOCHEMICAL FAILURE PATTERNS quality of life DECISION-ANALYSIS radiation therapy TRIAL CONFORMAL RADIOTHERAPY prostate social epidemiology BIOCHEMICAL CONTROL PROGNOSTIC MODELS PELVIC IRRADIATION HEALTH OVARIAN-CANCER RISK AB (Purpose:) under bar We evaluated whether posttreatment ETHNIC Gleason score and PSA stage-all of Prentice's requirements were not treatment recommendations WOMEN on Radiation Therapy Oncology Group Protocol 92-02 From June 1992 to time to PSADT (assuming first-order kinetics for a minimum of 3 rising REGISTRY BREAST-CANCER INTENSITY-MODULATED RADIOTHERAPY indicating that the effect of PSADT on CSS was not independent of met of prostate cancer is not fully explained by PSADT (c) 2006 Elsevier Medicare FOLLOW-UP Conformal radiotherapy IMMEDIATE GENE disparities EFFICACY Inc Urology & Nephrology DISABILITY QUALITY-OF-LIFE GRADE biochemical failure (Results: ) under bar After a median follow-up time of 59 years PSA measurements) and cancer-specific survival (CSS) prognostic models External beam radiotherapy MORTALITY CLINICAL-TRIAL AGE BEAM RADIATION-THERAPY prostate carcinoma 514 men with localized prostate cancer measurements in a cohort of 1 comorbidity CONFORMAL RADIATION-THERAPY PHASE-III TRENDS (T2c-4 and PSA level < 150 ng cancer RACIAL DEATH we tested if PSADT was prognostic and Cox proportional hazards model outcomes (Conclusions) under bar Prostatic specific antigen doubling time is administrative data PSA ERA (P-Cox = 04) The significant posttreatment PSADTs were also LOW-RISK SYMPTOMS EPIDEMIOLOGY Prostate cancer HISTORY 3-DIMENSIONAL RADIOTHERAPY Appropriateness criteria independent of randomized treatment in this cohort The endpoints were survey significant predictors of CSS (P-Cox < 0001) After adjusting for T AGONISTS PSA ERA (Methods and Materials: ) under bar We analyzed posttreatment PSA HORMONE Oncology Gleason score or in combination with 24 65-70 Gy of radiation therapy (n = 761) ALL-CAUSE MORTALITY PSADT < 6 months (pc < 0001) 0002)-PSADT < 9 months (P-Cox < DEFINITION and PSADT < 12 months (P-Cox < 0001) but not for PSADT < 3 0001) multi-institutional analysis randomized treatment was a significant predictor for CSS (p(Cox) = months of adjuvant androgen deprivation (n = 753) Using an adjusted ANDROGEN SUPPRESSION SURVIVAL SURVIVAL ADVANTAGE men were randomized to neoadjuvant androgen deprivation and April 1995 metastasis RECTAL BALLOON DOSE-VOLUME HISTOGRAMS prostatic-specific antigen doubling time (PSADT) was predictive of GLEASON prostate cancer mortality by testing the Prentice requirements for a Gleason pattern AMERICAN SOCIETY the risk of dying requirements for a surrogate endpoint of CSS Thus surrogate endpoint MANAGEMENT ORGAN MOTION long-term outcome BLACK but did not meet all of Prentice's significantly associated with CSS HEALTH STATES PELVIC LYMPHADENECTOMY NONCARRIERS ANTIGEN DENSITY PROGNOSTIC-SIGNIFICANCE EXTRACAPSULAR EXTENSION mortality preferences the randomized treatment CONTROLLED-TRIAL survival analysis SOCIOECONOMIC-STATUS treated and monitored prospectively mL) DIFFERENCES POSTOPERATIVE NOMOGRAM PCR ANDROGEN DEPRIVATION HORMONAL-THERAPY RANDOMIZED REGRESSION ADVANCED PROSTATE-CANCER SURVIVORS CORONARY-ARTERY-DISEASE PREOPERATIVE NOMOGRAM dose escalation THERAPY PATIENT PREFERENCES
Last updated on Thursday, April 02, 2020